Sarcopenia in gastric cancer and its impact on early postoperative outcome

Q3 Medicine
Mira Sudam Wagh , Arun K. Balan , Arun Peter Mathew , C.A. Rakesh , Jagath Krishna , K. Chandramohan , Madhu Muralee
{"title":"Sarcopenia in gastric cancer and its impact on early postoperative outcome","authors":"Mira Sudam Wagh ,&nbsp;Arun K. Balan ,&nbsp;Arun Peter Mathew ,&nbsp;C.A. Rakesh ,&nbsp;Jagath Krishna ,&nbsp;K. Chandramohan ,&nbsp;Madhu Muralee","doi":"10.1016/j.ctarc.2024.100829","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Sarcopenia, defined as progressive and generalised loss of skeletal muscle mass, quality, and strength, is considered as a poor prognostic factor in cancer. Outcomes in oncology mainly focus on survival related to disease and treatment. Other factors affecting the end result get less attention. This study was conducted with the aim to determine presence of sarcopenia in operable gastric cancer, factors positively correlating with presence of sarcopenia and its impact on early postoperative outcomes.</p></div><div><h3>Methodology</h3><p>This is a prospective study conducted from January 2020 to December 2021 in a tertiary care cancer hospital. All patients with adenocarcinoma stomach planned for curative intent surgery were assessed for sarcopenia by measuring hand grip strength(HGS) and skeletal muscle index(SMI). Comparison was made between patient and tumour related factors in patients with and without sarcopenia and impact of sarcopenia on early postoperative outcome was assessed.</p></div><div><h3>Results</h3><p>74 patients were assessed for sarcopenia. 32 (43.2 %) were patients diagnosed with sarcopenia. Advanced age(<em>p</em> = 0.040), low BMI (<em>p</em> &lt; 0.001), gastric outlet obstruction (<em>p</em> = 0.020) and urgent surgery (<em>p</em> = 0.002) positively correlated with sarcopenia. Curative resection was done in 68(91.89 %) patients and these patients were evaluated for early postoperative outcomes. 18 (26.5 %) patients had complications of Clavien Dindo grade 3 or above. Sarcopenia was not significantly associated with major postoperative complications(<em>p</em> = 0.857).</p></div><div><h3>Conclusion</h3><p>Sarcopenia, though associated with a substantial proportion of patients with gastric cancer, does not significantly affect early postoperative complications in a high volume oncology centre .</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"40 ","pages":"Article 100829"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000418/pdfft?md5=2072b55a4a18ef912b997cd606da6570&pid=1-s2.0-S2468294224000418-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294224000418","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Sarcopenia, defined as progressive and generalised loss of skeletal muscle mass, quality, and strength, is considered as a poor prognostic factor in cancer. Outcomes in oncology mainly focus on survival related to disease and treatment. Other factors affecting the end result get less attention. This study was conducted with the aim to determine presence of sarcopenia in operable gastric cancer, factors positively correlating with presence of sarcopenia and its impact on early postoperative outcomes.

Methodology

This is a prospective study conducted from January 2020 to December 2021 in a tertiary care cancer hospital. All patients with adenocarcinoma stomach planned for curative intent surgery were assessed for sarcopenia by measuring hand grip strength(HGS) and skeletal muscle index(SMI). Comparison was made between patient and tumour related factors in patients with and without sarcopenia and impact of sarcopenia on early postoperative outcome was assessed.

Results

74 patients were assessed for sarcopenia. 32 (43.2 %) were patients diagnosed with sarcopenia. Advanced age(p = 0.040), low BMI (p < 0.001), gastric outlet obstruction (p = 0.020) and urgent surgery (p = 0.002) positively correlated with sarcopenia. Curative resection was done in 68(91.89 %) patients and these patients were evaluated for early postoperative outcomes. 18 (26.5 %) patients had complications of Clavien Dindo grade 3 or above. Sarcopenia was not significantly associated with major postoperative complications(p = 0.857).

Conclusion

Sarcopenia, though associated with a substantial proportion of patients with gastric cancer, does not significantly affect early postoperative complications in a high volume oncology centre .

胃癌患者的肌肉疏松症及其对术后早期预后的影响
背景:肌肉疏松症是指骨骼肌质量、质量和力量的进行性和普遍性丧失,被认为是癌症的不良预后因素。肿瘤学的结果主要集中在与疾病和治疗相关的存活率上。而影响最终结果的其他因素则较少受到关注。本研究旨在确定可手术胃癌患者是否存在肌肉疏松症、与肌肉疏松症存在正相关的因素及其对术后早期预后的影响:这是一项前瞻性研究,于 2020 年 1 月至 2021 年 12 月在一家三级癌症医院进行。通过测量手部握力(HGS)和骨骼肌指数(SMI),对所有计划进行根治性手术的胃腺癌患者进行肌肉疏松症评估。比较有无肌肉疏松症患者的患者和肿瘤相关因素,并评估肌肉疏松症对术后早期预后的影响:74名患者接受了肌肉疏松症评估。结果:74 名患者接受了肌肉疏松症评估,其中 32 人(43.2%)被确诊为肌肉疏松症患者。高龄(p = 0.040)、低体重指数(p < 0.001)、胃出口梗阻(p = 0.020)和紧急手术(p = 0.002)与肌肉疏松症呈正相关。68例(91.89%)患者接受了根治性切除术,并对这些患者的术后早期效果进行了评估。有 18 名患者(26.5%)出现了 Clavien Dindo 3 级或以上的并发症。肌肉疏松症与主要术后并发症无明显关联(P = 0.857):尽管相当一部分胃癌患者都患有肌肉疏松症,但这并不会明显影响大手术量肿瘤中心的早期术后并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信